Samsung Biologics (207940) 🔎 In-depth
KOSPI · Price as of 2026-11-12 · Metrics 2026-11-13 · In-depth research 2026-11-07
Samsung Biologics is a contract development and manufacturing organization (CDMO): it makes biologic drugs such as antibodies on behalf of the global pharmaceutical companies that developed them, and its combined capacity of 845,000 liters across Songdo and Rockville in the US is the largest among the major players. Q3 2026 revenue rose 18.5% to ₩1.4903 trillion, but operating margin slipped to 42.9% from 50.4% a year earlier. The company raised its full-year revenue guidance to ₩5.4684 trillion (+20%), and is funding most of the price of a Swiss peptide manufacturer through a rights offering of about ₩2.665 trillion. A steady flow of long-term new contracts and net cash of around ₩1.5 trillion are clear strengths. The key condition behind a forward P/E of 38.72x is whether margins can climb back into the 43% range despite a stronger won, 4.9% dilution from the new shares and capacity additions by overseas rivals.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
Data sources
Prices & market cap from the FSC securities price API (data.go.kr) · filings & financials from OpenDART (FSS) · listings from the Korea Exchange.
Prices as of 2026-11-12. Methodology is public on the methodology page.
30-second brief
Auto-extracted from the computed values.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “CDMO & Biosimilars” (Biotech & Pharmaceuticals), a type typically read first through forward P/E.
CDMO and biosimilar players see future utilization and profit hinge on large capacity build-outs and new supply contracts. Because it is the earnings still to come — reflecting fresh orders and added capacity — that drives the price, forward P/E, based on expected earnings, is the first lens.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 30.3% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 25.8% higher than a year earlier.
- ROE is 23.7% (controlling-interest basis). It is above the sector average.
- Operating margin is 46.1%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2025-12-31
Largest shareholder Samsung C&T 43.06% (individual)
Controlling bloc incl. related parties 74.32%
With the controlling bloc holding 74%, control is very secure but the free float is thin.
🔎 In-depth analysis Reading
Samsung Biologics does not develop and market its own drugs. It manufactures biologic medicines that other pharmaceutical companies have developed, a business known as contract development and manufacturing (CDMO). The backbone is contract manufacturing: producing customers' drugs, such as antibody therapeutics, in large volumes in big culture tanks (bioreactors) and handing them over. In H1 2026, 97.6% of revenue came from these manufactured products and 2.4% from services such as cell-line and process development. Since spinning off its biosimilar business in November 2025 through a split-off (dividing the company in two and handing shares of the new company to existing shareholders), CDMO is the only business left. It has no in-house drug pipeline and no out-licensing deals, so the substance of the company's value lies in its manufacturing and development contracts with customers. Scale is the foundation of its competitiveness. Songdo Plants 1-5 provide 785,000 liters, and the 60,000-liter facility in Rockville, Maryland, acquired in March 2026, brings total capacity to 845,000 liters. According to the company's half-year filing, only four players have more than 300,000 liters of capacity: this company, Lonza of Switzerland, WuXi Biologics of China and Fujifilm of Japan, and Samsung Biologics is the largest of them. In Q3, Plants 1-4 ran at full utilization, Plant 5 began booking meaningful revenue from validation batches (a batch is a single production run), and the Rockville facility contributed revenue for the first time. The profit structure resembles a fixed-cost business. Most raw-material costs are settled by customers, so input-cost risk is small, but plant depreciation and labor costs are incurred regardless of volume. That makes plant utilization the main driver of margins. The company's disclosed batch-based utilization rate was 75.2% in 2024, 70.9% in 2025 and 69.9% in H1 2026: the existing plants are full, but there is still open capacity at the newly added Plant 5 and Rockville. Customers and revenue are mostly overseas. In H1 2026, 59.3% of revenue came from Europe, 23.1% from the US and 16.7% from Korea. The four largest customers accounted for 51.1% of revenue, and most contracts are denominated in dollars. Cumulative confirmed orders reached $21.9 billion by the end of Q3, or $24.5 billion including volumes that will be locked in when customers' products succeed in development or sites win approval. As of end-June, the undelivered balance of minimum committed volumes (quantities customers have firmly agreed to take) stood at $9.923 billion, with delivery dates stretching as far as 2037. The company has 117 manufacturing contracts and 184 development contracts, and products it makes have received 496 regulatory approvals in total (including 64 from the US FDA and 60 from the European Medicines Agency). It is also broadening the types of drugs it makes. A drug-substance facility for antibody-drug conjugates (ADCs, antibodies with a drug attached) has been running since March 2025, and ADC fill-finish and prefilled-syringe lines are planned by 2027. On November 6, 2026, its tender offer for PolyPeptide Group, a Swiss peptide contract manufacturer, closed with a 97.98% acceptance rate. PolyPeptide has production and research sites in the US, Belgium, France, Sweden and India, and posted H1 2026 revenue of ₩421.5 billion and net profit of ₩15.5 billion. About 68% of its H1 revenue came from treatments for metabolic diseases such as obesity and diabetes. Once the deal closes, demand for GLP-1 obesity drugs (medicines that mimic a hormone regulating appetite and blood sugar) will feed directly into Samsung Biologics' results as well.
The latest close is ₩1,449,000 and the market capitalization is ₩67.1 trillion. The price sits above its 20-day moving average (₩1,433,650) and above its 60-day moving average (₩1,428,533). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 52.5, a neutral level. The one-month change is +22.6%, the three-month change is -7.6%, and the position relative to the 52-week high is -26.3%. Relative strength versus the KOSPI is 52 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 52% of all stocks. Over the past three months it outpaced the index by 6.3%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
In the CDMO field, the first metric to look at is the forward P/E (share price as a multiple of this year's expected net profit). Because the business builds plants first and recoups the investment later through long-term contract volumes, future utilization and earnings, rather than past profit, set the value. Stacking a Q4 estimate on top of confirmed Q1-Q2 and preliminary Q3 results gives a forward P/E of 38.72x. The 39.43x P/E shown on screen is based on 2025 net profit of ₩1.7844 trillion, which includes ₩170 billion of profit from the biosimilar business spun off in November 2025. Restating 2025 profit for the remaining business only gives 41.6x, and using trailing 12-month profit (Q4 2025 to Q3 2026) gives 38.5x. Whichever yardstick is used, the multiple is around 40x, so stripping out last year's distortion does not change the level much. Profitability is high even by industry standards. The trailing 12-month operating margin (operating profit as a share of revenue) is 43.6%, above domestic peers Celltrion (30.0%) and ST Pharm (18.9%). ROE (how much the company earns on its equity in a year), based on trailing 12-month profit and end-Q3 equity, is 20.1%. These are hard to compare on the same footing with the sector median (3% operating margin, 1% ROE), which includes drug developers. The trend, however, is pointing down: quarterly operating margin fell for three straight quarters, from 46.2% in Q1 to 44.4% in Q2 and 42.9% in Q3. Q3 gross margin (the share of revenue left after production costs) was 49.6%, down from 58.6% a year earlier. The P/B (share price as a multiple of equity) shown on screen looks high because it uses end-Q1 equity. Dividing by end-Q3 equity of ₩8.6893 trillion gives 7.74x, and once the November offering is completed (payment on the 17th, new shares listed on the 30th) it falls to about 6.2x at the same share price. The balance sheet is comfortable. At end-Q3, cash plus short-term financial instruments totaled ₩2.3219 trillion against total borrowings of ₩799.4 billion, leaving the company with ₩1.5225 trillion more cash than debt, a net cash position. The debt ratio (liabilities relative to equity) was 45.8% at end-Q3, the borrowings ratio (interest-bearing debt relative to equity) was 9.2%, and the current ratio (assets convertible to cash within a year versus liabilities due within a year) was 202.0%. Enterprise-value metrics offer another check. EV (enterprise value) is market cap plus net debt (debt minus cash), roughly what it would cost to take over the whole company, debt and cash included. The EV metrics on screen do not count more than ₩1 trillion of short-term financial instruments as cash, so the company appears to carry net debt, but at end-Q3 it actually held net cash. Reflecting this, EV is ₩65.692 trillion, below market cap. That is 28.1x trailing 12-month operating profit (EV/EBIT) and 12.3x revenue (EV/Sales); on the company's revenue guidance for this year it is 12.0x, and on this year's estimated EBITDA (operating profit before depreciation and amortization) about 23.4x. Net cash makes these multiples slightly lower than the P/E, but a value of 28 times operating profit still assumes that 43%-range margins and long-term contracts continue. Cash generation is worth a look too. FCF yield (free cash flow, meaning operating cash minus capital spending, as a percentage of market cap) is roughly 2.3% on an approximate trailing 12-month basis. The FCF yield shown on screen is lower because it uses full-year 2025, when spending on Plant 5 was concentrated (₩1.3917 trillion of property, plant and equipment acquired in 2025). In H1 2026 alone, operating cash flow of ₩1.3925 trillion minus ₩190.6 billion of plant and intangible investment left ₩1.2019 trillion. However, a ₩1.9048 trillion investment plan for Plant 6 (180,000 liters, planned for completion in 2029) is waiting in the wings; if construction goes ahead, this yield could fall again. The balance sheet should stay solid after the offering and the acquisition. Net proceeds from the offering, after issuance costs, are about ₩2.6557 trillion. The PolyPeptide purchase price on a 100% basis is CHF 1,462.96 million, or ₩2.7062 trillion at the July 16 exchange rate. On a simple calculation, net cash of around ₩1.47 trillion would remain after the deal. The actual won amount will depend on the exchange rate on the settlement date, and the acquired company's debt will be added separately.
Five-year data (2021-2025) show revenue growing from ₩1.568 trillion in 2021 to ₩4.557 trillion in 2025. In between, however, the biosimilar subsidiary was brought into the consolidated accounts and then removed by the 2025 split-off, which changed the basis of comparison, so the five-year compound annual growth rate shown on screen is hard to take at face value. On a consistent basis excluding the biosimilar business, revenue over the last three years went from ₩2.9388 trillion in 2023 to ₩3.4971 trillion in 2024 and ₩4.557 trillion in 2025, with growth accelerating from 19.0% to 30.3%. Operating profit also rose from ₩1.2055 trillion to ₩1.3214 trillion and then ₩2.0692 trillion, an increase of 56.6% in 2025 alone. This year's results are in through Q3. Q1-Q3 revenue was ₩4.0684 trillion, up 24.4% year on year. Cumulative operating profit was ₩1.8073 trillion, up 17.3%, for a cumulative operating margin of 44.4%. Cumulative net profit was ₩1.291 trillion, 11.2% higher than the same period last year excluding the spun-off business. Quarterly revenue grew from ₩1.2571 trillion in Q1 to ₩1.3209 trillion in Q2 and ₩1.4903 trillion in Q3. In Q3 alone, revenue rose 18.5% to ₩1.4903 trillion, but operating profit rose just 1.0% to ₩640.1 billion, and operating margin dropped to 42.9% from 50.4% a year earlier. The company's Q3 presentation said the quarter included costs from disruptions to some production batches. Pre-tax profit (profit before corporate income tax) was ₩532.0 billion, ₩108.1 billion less than operating profit, and net profit fell 21.2% to ₩391.1 billion. The company did not separately explain the cause of this non-operating loss (losses arising outside the core business, such as from currency moves or interest). Non-operating results did, however, move in the same direction as the exchange rate: a gain in Q1, when the won was weak, turned into a loss in Q3 as the won strengthened. The Q3 figures are preliminary and have not yet been reviewed by the external auditor. Comparisons here use the same quarter of the previous year (YoY), because customer volumes are recognized batch by batch and quarterly revenue is lumpy. Last year, too, second-half revenue exceeded the first half, and Q4 operating margin (41.1%) was the lowest of the year, so comparing with the immediately preceding quarter can make seasonal differences look like growth or a slowdown. On October 21, the company raised this year's revenue guidance from ₩5.32 trillion (the midpoint of a +15-20% range) to ₩5.4684 trillion (+20%). It did not provide guidance for operating profit or net profit. Subtracting Q1-Q3 revenue from this guidance leaves about ₩1.4 trillion for Q4, about 6% less than Q3 and about 9% more than Q4 last year. The forward P/E of 38.72x is an in-house estimate built by stacking one more quarter on this revenue guidance. For Q4, the estimate assumes margins below Q3, since the strong won shrinks the won value of dollar contracts while won-denominated costs such as labor and depreciation stay the same; it also reflects the year-end cost concentration seen last year. Partly offsetting this, the Q3 batch-disruption costs are not expected to recur and volumes at Plant 5 and Rockville are rising. The result is operating profit growth of around 15% this year. Because of non-operating losses and taxes, however, net profit grows only around 7% excluding the spun-off business. Unlike 2025, when revenue rose more than 30%, this is a year in which profit growth fails to keep pace with revenue growth. The overall market is expanding. Industry data cited by the company in its offering registration statement project the biologics CDMO market to grow from $28.4 billion in 2026 (+14.6% year on year) to $43.9 billion in 2029, a compound annual rate of 15.6%. The company's Q1-Q3 revenue growth (24.4%) is above this market growth outlook.
Recent disclosures fall into four strands: results and guidance, new contracts, the share offering and acquisition, and labor relations. On results and guidance, the company released preliminary Q3 results on October 21 and raised this year's revenue guidance to ₩5.4684 trillion (+20%), confirming a quarter in which revenue growth continued but margins came down. On contracts, new deals kept coming in the second half. On September 10, it signed a $262.18 million (₩350.8 billion, through end-2033) contract with a European drugmaker, followed by a $68.75 million (₩93.5 billion, through end-2031) contract with a European drugmaker on October 2 and a $324.80 million (₩434.3 billion, through end-2031) contract with a global drugmaker on November 3. The November 3 contract equals 9.53% of 2025 revenue, the largest of the second-half filings. Existing customers also expanded: on September 10, a contract with the Swiss subsidiary of a global drugmaker was increased by $7.72 million and extended by one year to end-2028, and on November 2, a contract with a US drugmaker grew from $28.67 million to $55.37 million. Contract additions disclosed this year total about $1,092.43 million, combining four new contracts worth $926.53 million and increases of $165.90 million. Compared with 2025, when 10 new contracts worth about $4.5 billion (at initially disclosed amounts) were announced, the pace of disclosures has slowed. The offering and acquisition are the biggest change. When it approved the rights offering on August 28, the company amended the funding source for the PolyPeptide acquisition to 'funds raised through the rights offering, etc.' The issue price of the 2,270,000 new shares was fixed at ₩1,174,000 on November 5 (applying a 15% discount), for total proceeds of ₩2.66498 trillion. The largest shareholder, Samsung C&T, and affiliate Samsung Electronics disclosed on October 30 that they would subscribe for 100% of their allotted shares. Existing shareholders subscribe on November 9-10, the public offering runs November 12-13, payment is due on the 17th, and the new shares list on November 30. On the acquisition side, the tender offer closed on November 6 with a final acceptance rate of 97.98%. The remaining shares will be acquired through a compulsory squeeze-out under Swiss law to secure 100%. Payment will be made in cash within 10 trading days after merger-control approvals in each country, and the scheduled transfer date was pushed back by a month, from November 30 to December 31, in an October 16 amendment. Labor relations are a risk the company itself flagged in its registration statement. The 2026 wage and collective bargaining agreement has not yet been concluded. A strike from April 28 to May 5 forced it to discard some work-in-progress (partly finished product), and the production stoppage cost it revenue opportunities. A first post-mediation session was held at the Incheon Regional Labor Relations Commission on September 8, and the company wrote that it cannot rule out further industrial action.
First, the points worth watching on the positive side. One, customer demand is being confirmed through contracts. The three new contracts signed with European and global drugmakers since September all run through 2031-2033, and all four filings this year amending existing contracts were increases or extensions. With Plants 1-4 already full, the speed at which such contracts fill the open capacity at Plant 5 and Rockville in the US will set future margins. If this continues and utilization rises from the 69.9% of H1, margins could recover quickly, given that fixed costs stay the same. Two, US tariff rules are relatively favorable to Korean-made products. On April 2, the US issued a Section 232 (Trade Expansion Act) proclamation imposing a base tariff of 100% on patented drugs, applied to all companies from September 29. But products from Korea, the EU, Japan and Switzerland are capped at 15%, including existing tariffs, and drugmakers that have signed both a most-favored-nation pricing agreement with the US government (a pledge to bring US drug prices in line with other advanced economies) and a US manufacturing agreement pay 0% until January 20, 2029. On August 31, the White House said 26 drugmakers, representing 89% of the branded-drug market, had signed such pricing agreements. Many large customers can qualify for the 0% rate, and Korean output is better placed than Chinese or Indian output, which has no cap. Still, volumes for customers without agreements face 15%, so there remains a reason to make US-bound product in US plants. The next milestone is what terms apply after the 2029 deadline. Three, regulation of Chinese competitors could trigger customer shifts. The US BIOSECURE Act became law in December 2025 as part of the National Defense Authorization Act, and the US Office of Management and Budget must publish its first list of 'biotechnology companies of concern' by December 18. If WuXi Biologics, the largest competitor, is on the list, demand to move production from customers tied to US government procurement could grow. However, a US court on August 7 blocked enforcement of the designation of affiliate WuXi AppTec as a Chinese military company, and WuXi Biologics still grew its order backlog (contracted volumes yet to be delivered) to $25.1 billion in H1. Even once a list is published, prohibitions take effect later, so any impact on earnings would come in 2027 or later. Four, the balance sheet supports expansion. Net cash was ₩1.5225 trillion at end-Q3, and the roughly ₩2.7 trillion acquisition price is being funded mostly through new equity rather than borrowing. With the two major shareholders pledging to take up their full allotments, funding uncertainty is low. Five, peptides add a new growth pillar. PolyPeptide, the company being acquired, grew H1 2026 revenue 41.6% to €236.6 million and raised its full-year revenue growth outlook to 25-30% (at constant currency). If peptide drugs for obesity and diabetes remain mainstream, they will add a new growth engine to a revenue base that has centered on antibodies. Now the points of caution. One, margins have declined for three straight quarters. Quarterly operating margin went 46.2% to 44.4% to 42.9%, and Q3 gross margin fell from 58.6% to 49.6% in a year. Contract manufacturing prices are set through long-term contracts with no public price benchmark, so margins ultimately depend on utilization and costs. On top of that, the US most-favored-nation pricing agreements include a commitment to launch new drugs at prices similar to those in other high-income countries. If customers' US drug prices fall, pressure to cut costs could spill over into price negotiations for contract manufacturing. If margins return to the 43% range or higher from Q4 onward, the current multiple will rest on firmer ground; if they fall below 40%, a multiple at the top of the peer range becomes hard to justify. Two, a strong won weighs on both revenue and profit. The won/dollar rate the company cited in its November 2 contract filing was ₩1,337.20, about 10% below the H1 average of ₩1,481.78, and the Bank of Korea said on October 22 that the exchange rate had 'fallen considerably.' Overseas customers account for 83% of revenue, contracts are in dollars, and the company has no derivative contracts to reduce currency risk. The same dollar contract therefore yields less won revenue while won-denominated costs stay the same. If the exchange rate stays near current levels, margin recovery will be slower; if it rises again, the effect reverses. According to the company's disclosed sensitivity, a 10% move in the dollar rate shifts pre-tax profit by about ₩62.5 billion. Three, large competing capacity comes online in a cluster in 2027-2029. Japan's Fujifilm pulled forward the start-up of eight additional 20,000-liter units at its Holly Springs plant in North Carolina by six months, to the end of fiscal 2027; the plant was also selected for an FDA pilot program that supports approval of new plants. WuXi Biologics is building 36,000 liters in Worcester in the US and has set 2029 as the readiness date for a 120,000-liter plant in Singapore. In Korea, Lotte Biologics' Songdo Plant 1 (120,000 liters) received approval for use in June. If these facilities come online on schedule, competition on price and terms for large new contracts will intensify. Customers wanting US production may look first to players with big US plants, while this company's only US site is the 60,000-liter Rockville facility. Four, some customers are bringing production in-house, and drug formats are changing. On October 22, Eli Lilly broke ground on a $5 billion ADC and antibody drug-substance and drug-product plant in Virginia. Such plants take years to build, so volumes will not leave right away, but the more large drugmakers produce in-house in the US, the less new volume they will outsource. WuXi Biologics said over 70% of its new projects in H1 were complex biologics such as bispecific antibodies and ADCs. As demand shifts toward complex formats, dedicated facilities such as ADC and fill lines matter more than large bioreactors, so it matters whether the fill-finish lines due by 2027 are completed on schedule. On the peptide side, Lilly's oral small-molecule obesity drug Foundayo was approved in the US in April. If pills like this take a large share of the market, growth in demand for peptide drug substance could slow. Five, share count and acquisition risk. When 2,270,000 new shares (4.90%) list on November 30, earnings per share will fall and multiples will rise by about 5% even at the same share price. PolyPeptide posted net losses for three straight years from 2023 to 2025 (₩36.1 billion in 2025) before turning profitable in H1 this year. Its early earnings contribution may be modest, and the won cost will vary with the regulatory approval timeline and the Swiss franc/won rate on the settlement date. Six, variables such as labor relations and interest rates remain. The 2026 wage and collective bargaining talks are still unresolved, and the company has not ruled out further industrial action. The US Federal Reserve raised its policy rate to 3.75-4.00% in September, and when it held in October, some officials favored further hikes. The company says its development customers are mainly small and mid-sized biotechs, which are affected by funding conditions. If rates stay high, early-stage development orders could be the first to shrink. The fact that this year's disclosed contract amount (about $1.09 billion) is smaller than last year's disclosed new-contract amount (about $4.5 billion) is worth reading alongside this trend. If the Plant 6 investment plan (₩1.9048 trillion) goes ahead, capacity will increase again, and so will the burden of filling it with new volume.
🔎 Valuation vs peers Fairly valued
Instead of the automatic sector group (pharma and biotech, which mixes drug developers and traditional drugmakers, with a median P/E of 37.59x, forward P/E of 37.59x and operating margin of 3%), this uses a hand-picked domestic set of biologics manufacturers centered on the site's 'CDMO and biosimilars' sub-sector, at current prices: Celltrion (large-scale antibody biosimilar production with big culture facilities; site forward P/E 37.59x), ST Pharm (oligonucleotide drug-substance contract manufacturing, a synthetic CDMO in the same family as the peptide business once PolyPeptide is added; forward 23.29x), Samsung Epis Holdings (the biosimilar holding company split off from this company in November 2025; forward 21.15x) and SK bioscience (vaccines and contract manufacturing; loss-making, so compared on P/B only), where Celltrion's forward P/E is the site's November estimate reflecting Q3 results and ST Pharm's and Samsung Epis Holdings' are the site's pre-Q3 (July) estimates converted at current share prices, while the real competitors, large overseas contract manufacturers (Lonza, WuXi Biologics, Fujifilm), are compared only qualitatively because the site has no figures for them on the same basis.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Celltrion | 44.99x | 2.75x | 7.19% |
| ST Pharm | 27.66x | 2.49x | 11.36% |
| Samsung Epis Holdings | 100.33x | 1.43x | 1.44% |
| SK Bioscience | — | 1.75x | -3.21% |
The forward P/E based on this year's expected net profit (share price as a multiple of this year's expected earnings) is 40.62x. That is higher than the forward P/Es of domestic peers that also mass-produce biologics (Celltrion 35.1x, ST Pharm 23.29x, Samsung Epis Holdings 21.15x), and about 3.7 times the 10.52x forward median for the broader sector, which mixes drug developers and traditional drugmakers. Much of this gap is explained by earning power. Dividing P/B (7.74x on end-Q3 equity) by ROE (how much the company earns on its equity in a year) of 20.1% gives 0.39x per percentage point of ROE, similar to Celltrion (0.35x). On top of that, a minimum-volume contract backlog running to 2037, the largest capacity among the major players and net cash of around ₩1.5 trillion support a high multiple. On the other hand, Q3 operating margin slipped to 42.9% and non-operating losses added to the pressure, so net profit growth this year is expected to be in the single digits. When the new shares list on November 30, the share count rises 4.9% and the multiple climbs to 40.7x at the same share price. A strong won, labor negotiations and capacity additions by overseas rivals will also test the margin recovery. There is therefore little basis for calling the current multiple, at the top of the peer range, 'undervalued.' The 39.43x P/E and the P/B shown on screen are based on 2025 net profit that includes ₩170 billion from the spun-off biosimilar business and on end-Q1 equity, so they are not the right yardstick for the company as it stands today. Recalculated for the remaining business, the P/E is 37.59x on 2025 earnings and 38.5x on trailing 12-month earnings. In conclusion, the multiple is higher than peers but within a range explained by profitability and contract visibility, so we view the stock as fairly valued. If margins return to the 43% range or higher from Q4 and Plant 5 and the Rockville facility in the US fill up, the valuation burden will ease quickly; if margins fall below 40%, the case for a high multiple weakens.
Price history Close · MA20 · MA60
The latest close is ₩1,449,000 and the market capitalization is ₩67.1 trillion. The price sits above its 20-day moving average (₩1,433,650) and above its 60-day moving average (₩1,428,533). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 52.5, a neutral level. The one-month change is +22.6%, the three-month change is -7.6%, and the position relative to the 52-week high is -26.3%. Relative strength versus the KOSPI is 52 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 52% of all stocks. Over the past three months it outpaced the index by 6.3%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +6.31% / 6M +42.78% / 12M -42.18%
Key metrics Computed vs sector median
Valuation
The P/E of 37.59x is above the sector median (13.58x). The P/B of 8.47x is above the sector median (1.04x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 23.7%, above the sector average (1.0%). The operating margin is 46.1%. The debt ratio is 51.4%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $2.2B | $2.6B | $3.4B | +30.31% ↑ faster |
| Operating profit | $903.6M | $990.5M | $1.6B | +56.60% ↑ faster |
| Net profit | $642.9M | $812.0M | $1.3B | +64.71% ↑ faster |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $2.2B | $2.2B | $2.6B | $3.4B |
| Operating profit | $402.8M | $737.3M | $903.6M | $990.5M | $1.6B |
| Net profit | $295.0M | $598.2M | $642.9M | $812.0M | $1.3B |
| Revenue CAGR | 4-yr avg 30.57% | ||||
Revenue rose 30.3% year over year (2023 ₩2.9 trillion → 2024 ₩3.5 trillion → 2025 ₩4.6 trillion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Operating profit rose 56.6% year over year. Profit is growing at an accelerating pace. Over the 5 years on record, revenue compound annual growth (CAGR) is 30.6%. The two-year revenue CAGR is 24.5%. In the most recent quarter (Q1 2026), revenue was 25.8% higher than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- ROE of 23.7% points to solid profitability.
- Revenue grew 30.3% year over year, a sign of growth.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-11-06M&ATender offer for Swiss peptide contract manufacturer PolyPeptide closes: final acceptance 97.98% (32,350,302 shares), with remaining shares to be acquired via compulsory squeeze-out under Swiss lawAcceptance cleared both the deal-completion threshold (about 66.7%) and the squeeze-out requirement (90%), leaving merger-control approvals in each country and the timing of settlement (scheduled for December 31) as the remaining variables. Source
- 2026-11-05EquityRights offering issue price fixed at ₩1,174,000: 2,270,000 new shares, total proceeds ₩2.66498 trillionShares outstanding rise 4.90% to 48,560,951 (payment on November 17, new shares listed on the 30th), and all proceeds go toward acquiring the PolyPeptide stake. Source
- 2026-11-03Update$324.80 million (₩434.3 billion) contract manufacturing deal with a global drugmaker, through end-2031At 9.53% of 2025 revenue, it is the largest contract disclosed in the second half and shows that long-term volumes from large drugmakers keep coming (no upfront or advance payment). Source
- 2026-11-02Update2020 contract manufacturing deal with a US drugmaker increased: from $28.67 million to $55.37 million, through end-2030An existing customer raised its volumes, nearly doubling the minimum guaranteed amount. Source
- 2026-10-30EquityLargest shareholder Samsung C&T (782,818 shares) and affiliate Samsung Electronics (567,503 shares) disclose plans to subscribe for 100% of their rights offering allotmentsMajor-shareholder participation totals about ₩1.5853 trillion at the first-round issue price, reducing funding uncertainty; post-offering stakes will be 42.66% and 30.92%, respectively. Source
- 2026-10-22UpdateEli Lilly breaks ground on a $5 billion ADC, antibody drug-substance and drug-product plant in Goochland, VirginiaLarge customers expanding in-house production in the US is, over the long run, a factor that could replace volumes they now outsource. Source
- 2026-10-22UpdateBank of Korea holds its base rate at 3.00% and notes the won/dollar exchange rate has 'fallen considerably'With 83% of revenue from overseas dollar contracts, a stronger won tends to lower revenue and margins as booked in won. Source
- 2026-10-21EarningsQ3 2026 preliminary consolidated results: revenue ₩1.4903 trillion (+18.5%), operating profit ₩640.1 billion (+1.0%), net profit ₩391.1 billion (-21.2%)Full utilization at Plants 1-4 and revenue from Plant 5 and Rockville grew the top line, but operating margin fell from 50.4% to 42.9%, and pre-tax profit came in ₩108.1 billion below operating profit. Source
- 2026-10-21IR2026 consolidated revenue guidance revised upward: from ₩5.32 trillion to ₩5.4684 trillion (+20% year on year)This implies about ₩1.4 trillion of revenue left for Q4, while guidance for operating profit and net profit is still left blank. Source
- 2026-10-16FilingScheduled transfer date for the PolyPeptide stake changed from 2026-11-30 to 2026-12-31The delay follows the regulatory approval timeline and pushes back, by the same amount, when the acquired company's results enter the consolidated accounts. Source
- 2026-10-02Update$68.75 million (₩93.5 billion) contract manufacturing deal with a European drugmaker (voluntary disclosure), through end-2031Equal to 2.05% of 2025 revenue, it shows new contracts continuing in the second half. Source
- 2026-09-29UpdateUS Section 232 tariff on patented drugs begins applying to all companies (some companies from July 31)Q4 is the first quarter of full application; Korean-made volumes for customers without pricing or manufacturing agreements face a 15% tariff. Source
- 2026-09-16UpdateUS Federal Reserve raises its policy rate by 0.25 percentage point (to 3.75-4.00%)Tighter funding conditions for small and mid-sized biotechs are one path through which new demand for development services could weaken. Source
- 2026-09-10UpdateNew $262.18 million (₩350.8 billion) contract manufacturing deal with a European drugmaker (through end-2033) and a $7,716,400 increase to a contract with the Swiss subsidiary of a global drugmakerThe new deal is a long-term contract equal to 7.70% of 2025 revenue, and the increase also extended the term by one year to end-2028. Source
- 2026-08-31UpdateWhite House adds nine companies to its most-favored-nation pricing agreements: 26 in total, covering 89% of the branded-drug marketMany large customers can now qualify for 0% tariffs, but pressure to lower new-drug prices could spill over into contract manufacturing price negotiations. Source
- 2026-08-28EquityRights offering approved (2,270,000 new shares), with the funding source for the PolyPeptide acquisition amended to 'funds raised through the rights offering, etc.'The need to fund the acquisition with borrowing disappeared, but the larger share count brings 4.90% dilution. Source
- 2026-08-25UpdateWuXi Biologics' H1 order backlog reaches $25.1 billion, with 123 new end-to-end projects (+43%)Orders at the largest competitor have not shrunk, a sign that customer shifts driven by US regulation have so far been limited. Source
- 2026-08-11UpdatePolyPeptide H1 revenue of €236.6 million (+41.6%); full-year revenue growth outlook raised to 25-30%Shows that the acquired company's growth is concentrated in peptide demand for obesity and diabetes (metabolic diseases account for about 68% of revenue). Source
- 2026-08-07UpdateUS federal district court issues a preliminary injunction blocking enforcement of WuXi AppTec's designation as a Chinese military company (1260H)Designation of the Chinese competitor could be delayed, pushing back the timing of any benefit from production shifting. Source
- 2026-07-08UpdateFujifilm brings forward start-up of eight 20,000-liter units at Holly Springs in the US by six months, to the end of fiscal 2027Large local US capacity arrives sooner, intensifying competition for new contracts with customers that want US production. Source
- 2026-06-08UpdateUS Department of Defense updates its list of Chinese military companies (1260H), adding WuXi AppTecThe BIOSECURE Act's designation route reached a large Chinese contract manufacturer for the first time, increasing pressure on customers to review their supply chains. Source
- 2026-04-02UpdateUS presidential proclamation sets Section 232 tariffs on patented drugs (100% base, 15% cap for Korean products, 0% or 20% for companies with agreements)A key rule that changes the cost for customers bringing Songdo-made product into the US and the incentive to produce locally in the US. Source
- 2026-04-01UpdateUS FDA approves Lilly's oral small-molecule GLP-1 obesity drug Foundayo (orforglipron)The arrival of a non-peptide obesity drug creates a factor that could substitute for demand at the peptide contract manufacturing business being acquired. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Sweep of the latest disclosures (as of today) | fetch_disclosures days=200 2026-11-06, base major 18 | base disclosures 2026-06-09. major 18 = ·approx. 7, 7, 4. major (8/14), revenue (10/21), PolyPeptide (8/28·10/16·11/6) | Confirmed | link |
| Q3 2026 consolidated results (preliminary) checked against the original filing | revenue 1 ₩490.3 billion, operating profit ₩640.1 billion, ₩532.0 billion(−19.7%), net profit ₩391.1 billion(−21.2%). 1~3 revenue 4 ₩68.4 billion·operating profit 1 ₩807.3 billion· 1 ₩757.3 billion·net profit 1 ₩291.0 billion | 3 IR : revenue ₩738.5 billion(49.6%)· ₩98.4 billion·EBITDA ₩751.5 billion(50.4%), 1~3 EBITDA 2 ₩125.3 billion(52.2%). operating profit ₩640.1 billion | Confirmed | link |
| Company's official 2026 full-year guidance | revenue 5 ₩468.4 billion, operating profit··net profit | (2026-01-21) 5 ₩320.0 billion. 3 IR ' +15~20% +20% ' | Confirmed | link |
| Quarter-stacked forward estimate (2026 net profit attributable to owners, forward P/E) | operating profit Q1 5,808+Q2 5,864+Q3 6,401+Q4 5,750=2 ₩382.3 billion → 2 3,223 → net profit 1 ₩731.7 billion → PER 67 2,145 ÷ 1 7,317 = 38.8x | — | Unverified | link |
| Key sub-sector metric: forward P/E recalculated | 38.8x, 40.7x | base sector_valuation.metric_value 34.61x | Mismatch | link |
| P/E (TTM) denominator updated | TTM net profit 1 ₩744.0 billion(2025Q4~2026Q3) 38.5x / net profit 1 ₩801.0 billion 37.3x | base PER 37.67x = 67 2,145 ÷ 2025 net profit 1 7,844 | Confirmed | link |
| P/B, ROE, debt ratio and current ratio denominators updated (end of Q3) | PBR: 7.74x, ROE 20.1%, : 45.8%, 202.0%, TTM operating margin 43.6%·net margin 32.6% | base PBR 8.48x·ROE 23.7%· 51.4%· 170.1%·operating margin 46.1%·net margin 39.0% | Mismatch | link |
| Enterprise value (EV) recalculated | 1 ₩522.5 billion → EV 65 ₩692.0 billion, EV/EBIT 28.1x(TTM)·27.6x, EV/Sales 12.3x(TTM)·12.0x, EV/EBITDA approx. 23.4x | base enterprise: +7,782, EV 67 9,927, EV/EBIT 30.63x, EV/Sales 14.12x, EV/EBITDA 26.25x | Mismatch | link |
| Cash capacity (net cash, FCF) | 1 ₩522.5 billion. 2026 FCF 1 ₩201.9 billion, 12 approx. 1 ₩574.7 billion → FCF approx. 2.3% | ₩1,392,488,374,186, ₩172,611,419,110, ₩17,993,318,800, ₩533,667,531,470 | Confirmed | link |
| Rights offering dilution (share count, proceeds) | 2,270,000, ₩1,174,000, ₩2,664,980,000,000, 2026-11-17, 2026-11-30,x 2026-01-01 → 48,560,951 | (₩1,452,000) 70 ₩510.5 billion, PER 40.7x | Confirmed | link |
| PolyPeptide stake acquisition terms and progress | CHF 44.31, 33,016,411 CHF 1,462,957,171, 7/16 (CHF/KRW 1,849.79) 2 ₩706.2 billion. 97.98%, 100% , 2026-12-31, · 10 | 2025 revenue ₩669.2 billion· ₩36.1 billion, 2025 1 4,102· 8,287· ₩581.5 billion | Confirmed | link |
| Orders and production capacity (Q3 investor relations materials) | CMO 219 , CMO 117·CDO 184, CMO 496 | 6 99 2,300 , 84 5 , 2026 69.9% | Confirmed | link |
| Drug pipeline and licensing contract terms | — | 2025-11-01 | Confirmed | link |
| Audit flag review and annual financials checked against the original filing | audit passed, 13, flag 0. base growth.history 2025 revenue ₩4,556,971,695,180·operating profit ₩2,069,221,266,630·net profit ₩1,784,352,060,593 | 2025 : revenue 4,556,972·operating profit 2,069,221·net profit 1,784,352 | Confirmed | link |
Recent filings Source
- 2026-06-09Single supply/sales contract (amended)
- 2026-06-01Disclosure
- 2026-06-01OwnershipLargest-shareholder ownership change report
- 2026-06-01Disclosure
- 2026-06-01Corporate governance report
- 2026-06-01Large-business-group status disclosure
- 2026-05-20OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15PeriodicQuarterly report
- 2026-05-15PeriodicAnnual business report (amended)
- 2026-05-04OwnershipLargest-shareholder ownership change report
- 2026-04-24Disclosure
- 2026-04-22EarningsFair-disclosure notice
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.